Incremento de supervivencia en melanoma - page 13

N=834
Keynote 006
• Primary end points: PFS and OS
• Secondary end points: ORR, duration of
response, safety
35% Prior therapy
18% BRAF mutant tx naive
Robert et al. N Eng J Med 2015; Schachter et al. SMR 2015; Schachter ASCO 2016
Max 2 years